Researchers are calling for a strengthening of the Antarctic Treaty in the face of expected growth in the search for organisms on the continent that may provide lucrative material for biotechnology companies. The call comes because of the background of scientific collaboration that has been in place for more than 40 years which has helped maintain an almost unique international collaboration to preserve the continent and the species that inhabit it.
But the environment of the polar continent makes it especially appealing for biotech companies. Explorers first laid eyes on the islands of the Antarctic peninsular in 1819. They had speculated that a southern continent existed and given it a name -Terra incognita Australis, the unknown southern land. In 1820, the Russian explorer Fabian Gottlieb von Bellingshausen became the first person to see the mainland. The first camp was set up by a Norwegian in 1899 and a flurry of survey trips followed so that by the 1940s, Antarctic exploration was no longer the preserve of privately funded entepreneurs as governments established bases on the continent.
Organisms that thrive in the frozen
The new report warns that so far biological prospecting in Antarctica has usually been carried out be consortia made up of public and private bodies, principally universities, research centres and biotechnology and pharmaceutical companies. "This has made it difficult to draw a clear line between scientific and commercial activities," it says.
The Antarctic Treaty group's advisory body, the Scientific Committee on Antarctic Research, also raised concerns about bioprospecting in a recent report. It stated: "While no current instance of harvesting for biotechnology is known, there are obvious environmental ramifications of the taking of animals and plants as a commercial venture." Their report concludes that bioprospecting should be watched closely as it "may develop into important pressures on Antarctic resources."
The new report highlights that developing commercial products from naturally occurring genetic resources or biochemichal processes is typically a long, expensive and uncertain process, Even so, annual sales derived from traditional knowledge using genetic resources are $3 billion for the cosmetics and personal care industry, $20 billion for the botanical medicine sector and $75 billion for the pharmaceutical industry. More than 60 per cent of the cancer drugs approved by the US Food and Drug Administration are of natural origin or are modelled on natural products.
Another concern is that companies with patents on Antarctic organisms, or extracts from them, may prevent scientists from working on them freely. Johnston says now is the time to deal with the issue. Regulations to control bioprospecting will have to be agreed upon by the many countries that control different parts of Antarctica. But if biotech companies start making agreements with individual governments, it will be much more difficult to reach a global agreement. "It's going to be much easier to put regulations in place that are effective and meaningful before there are vested interests," Johnston said. "It is imminent that biotechnology companies will take up bioprospecting companies and will be significant in the next 10 years. After that, the horse may have bolted." David Walton, chief scientist at the British Antarctic Survey said the Antarctic treaty group had recently discussed bioprospecting. "As always, it's up to individual states to determine what will be agreed. Like all international activity it takes a long time to get everybody to understand what the problem is and do something about it," he said.
Johnston said getting regulations right in Antarctica now would set a precedent for other environments around the world where flora and fauna could attract biotech companies. "It's a way of showing how the world should deal with bioprospecting generally," he said.
The report concludes that although the physical impact of bioprospecting is currently addressed by the treaty, establishing the legal and policy basis that controls the commercialisation of genetic resources, in line with the basic principles of the treaty as well as equity and fairness, is a more complex matter.
